Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Samsung starts phase III trial for Humira biosimilar
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jun 24, 2014 14:10:55
Samsung Bioepis will start its phase III clinical trial for the biosimilar of Humira in four hospitals as the Ministry of Food and Drug Safety gave green light.

Samsung will compare the efficacy and safety of its biosmilar with Humira. It is also conducting phase I clinical trials of the biosmilar in other countries to enter the global market.

Smasung is currently working on the biosimilars of Enbrel, Remicade and Herceptin. The phase III clinical trial of its Enbrel biosimilar is almost completed and the other trials are halfway done.

Several Korean companies are developing biosimilars, but only the two biosimilars, Ramsima and Herzuma, are approved so far.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com